Clinical trials: Advanced Rectal Cancers
Gastric Cancer, Colorectal Cancer
A Phase 1 Study of SHR-A1811 in Patients With Selected HER2 Expressing Tumors
This is a single arm, open-label, dose escalation, PK expansion and efficacy expansion study of phase I. The purpose of this study is to assess the tolerability, safety, pharmacokinetics and immunogenicity of SHR-A1811 and…
- Trial name
- NCT04513223
- Testing
- SHR-A1811
- Where
- China
- Volunteers
- 101 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Colorectal Cancer
Intensity-Modulated Radiation Therapy With Incorporated Boost and Capecitabine Before Surgery in Treating Patients With Locally Advanced Rectal Cancer
RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. Intensity-modulated radiation therapy (radiation directed at the tumor more precisely than in standard radiation therapy) with incorporated boost (an…
- Trial name
- NCT00084591
- Testing
- capecitabine, conventional surgery, neoadjuvant therapy
- Where
- United States
- Sponsor
- Fox Chase Cancer Center
Rectal Cancer, Locally Advanced
SCRT Sequential Penpulimab in Combination With CAPEOX in the Neoadjuvant Treatment of MSS Locally Advanced Rectal Cancer
The goal of this phase 2 study is to learn about the efficacy and safety of short-course radiotherapy (SCRT) sequential Penpulimab in combination with CAPEOX in the neoadjuvant treatment of microsatellite stable (MSS) locally…
- Trial name
- SPARC (NCT05576480)
- Testing
- Short-course radiotherapy, Penpulimab, CAPEOX
- Where
- China
- Volunteers
- 55 people
- Sponsor
- Ruijin Hospital
Metastasis Colorectal Cancer, Colon Cancer
Study of Fruquintinib Combined With Tegafur Gimeracil Oteracil in Patients With Metastatic Colorectal Cancer
This is an Open, Single-arm, Multicenter, Prospective Phase II Study of Fuquinitinib Combined With Tegafur Gimeracil Oteracil in the Third-line Treatment of Patients With Advanced Metastatic CRC
- Conditions
- Metastasis Colorectal Cancer, Colon Cancer, Rectal Cancer
- Trial name
- NCT06255379
- Testing
- Fuquinitinib+Tegafur Gimeracil Oteracil
- Where
- China
- Volunteers
- 52 people
- Sponsor
- Guangzhou University of Traditional Chinese Medicine
KRAS P.G12C, Non-small Cell Lung Cancer
Phase 1/2a Study of JAB-21822 Plus JAB-3312 in Patients With Advanced Solid Tumors Harboring KRAS p.G12C Mutation
This is a multicenter, open-label phase 1/2a study consisting of two parts: dose escalation phase and dose expansion phase. The objective of the dose escalation phase is to evaluate the safety, tolerability and pharmacokinetics…
- Conditions
- KRAS P.G12C, Non-small Cell Lung Cancer, Colorectal Cancer, Pancreatic Ductal Carcinoma
- Trial name
- NCT05288205
- Testing
- JAB-21822, JAB-3312
- Where
- 27 sites in China
- Volunteers
- 240 people
- Sponsor
- Allist Pharmaceuticals, Inc.
Neoplasms, Rectal
A Study of the Duration of Dostarlimab in Untreated Mismatch Repair Deficient (dMMR)/ Microsatellite Instability-high (MSI-H) Locally Advanced Rectal Cancer
This study is conducted in adults with rectal cancer that has a certain genetic type. The main goal is to find out whether a longer treatment period with dostarlimab can help more participants have a complete response to…
- Trial name
- DuraSTAR (NCT07740720)
- Testing
- Dostarlimab
- Volunteers
- 90 people
- Sponsor
- GlaxoSmithKline
Colon Cancer
A Prospective Study Utilizing Circulating Cell Free DNA (cfDNA) Use in the Detection of RAS Mutations in Patients With Advanced Colorectal Cancer.
Colorectal cancer remains the commonest cancer among men, and third commonest among women in Saudi Arabia . Presentation with metastatic disease occurs in almost one third of patients , with 5-year survival decreasing…
- Trial name
- NCT04775862
- Testing
- investigator choice re-challenge with anti EGFR Rx
- Where
- Saudi Arabia
- Volunteers
- 60 people
- Sponsor
- National Guard Health Affairs
Colorectal Neoplasms, Breast Neoplasms
A Multicenter Phase 2 Study of CI-1040 in Patients With Advanced Nonsmall-Cell Lung, Breast, Colon and Pancreatic Cancer
CI-1040 is an experimental drug that is being tested in patients who have advanced colorectal and lung cancer who failed no more than one prior chemotherapy regimen, breast cancer who have failed no more than 2 prior regimens and…
- Conditions
- Colorectal Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Pancreatic Neoplasms
- Trial name
- NCT00034827
- Testing
- CI-1040
- Where
- 30 sites in United States
- Volunteers
- 172 people
- Sponsor
- Pfizer
Advanced or Metastatic Solid Tumors
A Phase 1 Study to Evaluate TGI-6 in Subjects With Locally Advanced/Metastatic Solid Tumors
A Phase 1 Study to Evaluate TGI-6 in Subjects with Locally Advanced/Metastatic Solid Tumors
- Trial name
- NCT06374173
- Testing
- TGI-6 Injection
- Where
- China
- Volunteers
- 123 people
- Sponsor
- Hefei TG ImmunoPharma Co., Ltd.
Breast Cancer, Colorectal Cancer
Shark Cartilage in Treating Patients With Advanced Colorectal or Breast Cancer
RATIONALE: Shark cartilage extract may help shrink or slow the growth of colorectal cancer or breast cancer cells. PURPOSE: Randomized phase III trial to determine the effectiveness of shark cartilage in treating patients who…
- Trial name
- NCT00026117
- Testing
- BenFin
- Where
- 16 sites in United States
- Volunteers
- 88 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Rectal Neoplasms Malignant, Rectum Carcinoma
Induction and Consolidation Chemotherapy in Patients With Locally Advanced CRM-positive Rectal Cancer
The purpose of this study is to determine whether the addition of 2 cycles of induction CapOx chemotherapy and 2 cycles of consolidation CapOx chemotherapy to standard chemoradiation improves 3-year disease-free survival in…
- Conditions
- Rectal Neoplasms Malignant, Rectum Carcinoma, Rectal Cancer
- Trial name
- RuCorT-03 (NCT04135313)
- Testing
- Capecitabine, Oxaliplatin, Radiotherapy
- Where
- Russia
- Volunteers
- 540 people
- Sponsor
- Blokhin's Russian Cancer Research Center
Locally Advanced Rectal Cancer
Neoadjuvant Long-course Chemoradiation Plus PD-1 Blockade for Mid-low Locally Advanced Rectal Cancer
This is a phase II/III, multi-center, open-label, 3-arm, randomized controlled trial assessing the efficacy and safety of neoadjuvant long-course chemoradiation combined with Tislelizumab (PD-1 inhibitor) and subsequent TME…
- Trial name
- NCT05245474
- Testing
- Long-course chemoradiation, with or without Tislelizumab (PD-1 inhibitor)
- Where
- 8 sites in China
- Volunteers
- 186 people
- Sponsor
- Beijing Friendship Hospital
Ewing Sarcoma, PEComa
Nivolumab (Opdivo®) Plus ABI-009 (Nab-rapamycin) for Advanced Sarcoma and Certain Cancers
This study investigates the safety/toxicity and potential anti-tumor activity of sequential administration of nivolumab and escalating doses of the mammalian target of rapamycin (mTOR) inhibitor nab-rapamycin (ABI-009) in…
- Conditions
- Ewing Sarcoma, PEComa, Epithelioid Sarcoma, Desmoid Tumor
- Trial name
- NCT03190174
- Testing
- Nab-Rapamycin, Nivolumab
- Where
- United States
- Volunteers
- 34 people
- Sponsor
- Sarcoma Oncology Research Center, LLC
Colorectal Cancer
Simvastatin and Panitumumab in Treating Patients With Advanced or Metastatic Colorectal Cancer
RATIONALE: Simvastatin may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Monoclonal antibodies, such as panitumumab, can block tumor growth in different ways.
- Trial name
- NCT01110785
- Testing
- panitumumab, simvastatin, laboratory biomarker analysis
- Where
- 4 sites in Netherlands
- Volunteers
- 46 people
- Sponsor
- Leiden University Medical Center
Colorectal Cancer
T Regulatory Lymphocytes (Treg) Depletion for Cancer Treatment Efficacy and Safety Study
T regulatory lymphocytes were shown to be partly responsible for immune tolerance to cancer cells. In that respect these cells oppose to the mounting of an efficacious immune response needed to cure cancer.
- Trial name
- STARTREK (NCT00986518)
- Testing
- Adaptive autologous cell immunotherapy
- Where
- France
- Volunteers
- 5 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Organ Preservation, Rectal Cancer
Organ Preservation in Rectal Cancer: Contact X-ray Brachytherapy vs Extending the Waiting Interval and Local Excision
The goal of this prospective phase II feasibility study is to evaluate two additional local treatment options in rectal cancer patients with a good clinical response after neoadjuvant (chemo)radiation: contact x-ray brachytherapy…
- Conditions
- Organ Preservation, Rectal Cancer, Quality of Life, Locally Advanced Rectal Carcinoma
- Trial name
- OPAXX (NCT05772923)
- Testing
- Contact x-ray brachytherapy, Local excision
- Where
- 7 sites in Netherlands
- Volunteers
- 168 people
- Sponsor
- The Netherlands Cancer Institute
Rectal Cancer
Avelumab With Chemoradiation in Locally Advanced Rectal Cancer
This trial is investigating the inclusion of avelumab post long-course chemo-radiotherapy in patients with resectable locally advanced rectal cancer.
- Trial name
- NCT03299660
- Testing
- Avelumab, 5 Fluorouracil, Capecitabine Pill
- Where
- 7 sites in Australia
- Volunteers
- 37 people
- Sponsor
- Peter MacCallum Cancer Centre, Australia
Colorectal Cancer, Triple Negative Breast Cancer
A Study of Navicixizumab Monotherapy or in Combination in Patients With Select Advanced Solid Tumors
This is a study of navicixizumab monotherapy or in combination with paclitaxel or irinotecan in patients with advanced cancer. Patients will be enrolled into one of the following cancer cohorts: Cohort A: CRC Cohort B: Gastric…
- Conditions
- Colorectal Cancer, Triple Negative Breast Cancer, Gastric Cancer, Ovarian Cancer
- Trial name
- NCT05453825
- Testing
- navicixizumab+paclitaxel, navicixizumab+irinotecan, navicixizumab monotherapy
- Where
- 8 sites in United States
- Volunteers
- 180 people
- Sponsor
- OncXerna Theraputics, Inc.
Bladder Cancer, Breast Cancer
LMB-9 Immunotoxin in Treating Patients With Advanced Colon, Breast, Non-small Cell Lung, Bladder, Pancreatic, or Ovarian Cancer
Phase I trial to study the effectiveness of LMB-9 immunotoxin in treating patients who have advanced colon, breast, non-small cell lung, bladder, pancreatic, or ovarian cancer.
- Conditions
- Bladder Cancer, Breast Cancer, Colorectal Cancer, Lung Cancer
- Trial name
- NCT00005858
- Testing
- LMB-9 immunotoxin
- Where
- 2 sites in United States
- Volunteers
- 25 people
- Sponsor
- University of Maryland, Baltimore
Rectal Neoplasms
CORE: Capecitabine, Oxaliplatin, Radiotherapy and Excision
Primary objective: Pathological complete response (ypT0N0) rate Secondary objectives: Histopathological R0 resection rate Pathological downstaging (ypT0-T2N0) rate One month surgical complication rate Predictive value of…
- Trial name
- NCT00174616
- Testing
- Oxaliplatin, capecitabine, radiotherapy
- Where
- 7 sites in Belgium, France and 5 more
- Volunteers
- 87 people
- Sponsor
- Sanofi
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.